Itzayana Ortega-Franco

Itzayana Ortega-Franco

Auto-generated profile, based on publicly available information

Itzayana Ortega-Franco

Faculty of Medicine, Oncology Service, Hospital Universitario “Dr José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2025 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
RGRosalaura Virginia Villarreal Gonzalez
Rosalaura Virginia Villarreal Gonzalez
LFLeslie Astrid De la Fuente
Leslie Astrid De la Fuente
DCDiana Cadenas-García
Diana Cadenas-García
IOItzayana Ortega-Franco
Itzayana Ortega-Franco
MMMarianela Madrazo-Morales
Marianela Madrazo-Morales
OGOscar Vidal Gutierrez
Oscar Vidal Gutierrez
Introduction: Chemotherapy and monoclonal antibodies are increasingly associated with hypersensitivity reactions (HSRs), including anaphylaxis. Desensitization modulates allergic responses to drugs, facilitating temporary tolerance to full therapeutic doses. Methods: Observational, descriptive, ambispective study from August 2020 to August 2024, including cancer patients who came for treatment administration and developed a hypersensitivity reaction, and underwent 3-bag 12-step desensitization in 5.67 h. Demographic variables, atopic and oncological history, hypersensitivity reactions, breakthrough reactions (BTR) during desensitization, and safety of the protocols were reported. Results: 927 desensitization in 219 patients, 20.7% with personal atopy and 84% female. The most common oncological diagnoses were: breast cancer (23.3%), ovarian (22.1%), and cervical (15.9%). The drugs of the most hypersensitivity reactions were Paclitaxel 372 (40.2%), Carboplatin 172 (18.7%), Oxaliplatin 66 (7.1%), Docetaxel 59 (6.4%), Rituximab 40 (4.3%) and Trastuzumab 40 (4.3%). The most frequent hypersensitivity reactions were cutaneous 172 (18.6%), respiratory 173 (18.7%) and cardiovascular 165 (17.8%) with a severity scale of Brown I 12.1%, Brown II 43.3% and Brown III 44.6%. During desensitization 80/927 cases (8.6%) had breakthrough reactions: cutaneous 56 (6%), respiratory 18 (1.9%) and cardiovascular 17 (1.8%), of which the majority were mild reactions. All patients completed their desensitization with no deaths reported. Conclusions: Our study reports that patients undergoing desensitization protocols had a lower percentage of breakthrough reactions compared to the previous hypersensitivity reactions, showing that this procedure is safe and effective to continue first-line oncological treatment.